Purdue Looks To Patent Portfolio, FDA Guidance To Delay OxyContin Generics
This article was originally published in The Pink Sheet Daily
Federal Circuit finds four OxyContin patents invalid, but authorized generics will continue to be only ones available for the near future.
You may also be interested in...
Sen. Alexander and others remain optimistic as several holds and a filibuster threat emerge.
Agency plans to issue 102 new and revised draft guidances this year, including those on use of multiple endpoints in clinical trials, 180-day exclusivity, and ANDA refuse-to-receive standards.
Generic manufacturer could begin selling either its own product or an authorized generic of the controlled-release opioid as early as Jan. 1, 2016.